Background. FN18-CRM9 is a CD3-specific immunotoxin that is capable of
depleting CD3(+) T cells. Pretreatment of rhesus monkeys with this ag
ent before transplantation can induce donor-specific tolerance and ''s
plit tolerance'' to renal allografts. Methods. Heterotopic renal trans
plants were performed on monkeys that received posttransplant FN18-CRM
9. Histological and immunohistological staining, as well as analysis o
f the intragraft cytokine profile by reverse transcriptase polymerase
chain reaction, was performed on percutaneous allograft biopsies. Resu
lts. Experimental monkeys had significant prolongation of allograft su
rvival. Although an interstitial, mononuclear cell infiltrate was seen
in all of the renal transplants, there was minimal evidence of acute
cellular rejection. Histological evidence of alloantibody-mediated dam
age was detected 3 to 5 months after transplantation in the monkeys tr
eated with FN18-CRM9. Immunohistology demonstrated the reappearance of
CD3(+) and CD4(+) T cells, as well as CD20(+) B cells, in the grafts.
Cytokine analysis demonstrated expression of interferon-gamma. An int
act anti-donor IgG response was seen. Conclusion. Treatment of monkeys
with FN18-CRM9 immediately after transplantation significantly prolon
gs renal allograft survival. Allograft biopsies demonstrate a lack of
acute cellular rejection; however, alloantibody-mediated graft damage
and rejection occur, with an intact anti donor IgG response, The intra
graft expression of the interferon-gamma may reflect this ongoing hum
oral rejection. These data suggest that even a brief period of T-cell
allosensitization may lead to humorally mediated allograft damage. Eff
orts to achieve tolerance with posttransplant FN18-CRM9 will require m
odification of the protocol to deplete T cells before allosensitizatio
n exposure or to supplement the posttransplant immunomodification stra
tegy.